Vistagen Therapeutics Inc (VSTA) 5.5000 $VSTA VistaGen

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Vistagen Therapeutics Inc (VSTA) 5.5000 $VSTA

VistaGen Announces Nasdaq Listing and Pricing of $10.0 Million Public Offering
PR Newswire - Tue May 10, 6:36PM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA) (VistaGen or the Company), a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system (CNS), today announced its common stock will begin trading on The NASDAQ Capital Market under the symbol ''VTGN" on May 11, 2016. The Company also announced the pricing of its public offering of 2,352,942 shares of common stock and warrants to purchase up to 2,352,942 shares of common stock, at a combined price to the public of $4.25 for aggregate gross proceeds of approximately $10.0 million. The warrants will have an exercise price of $5.30, are exercisable immediately, and will have a term of five years. VistaGen has granted the underwriters a 45-day option to purchase up to 352,942 additional shares of common stock and/or warrants to purchase up to 352,942 additional shares to cover over-allotments, if any.

Nutrisystem (NTRI) Q1 Earnings, Revenues Top; '16 View Up
Zacks Equity Research - Zacks Investment Research - Wed May 04, 8:02AM CDT
Nutrisystem Inc. (NTRI) reported first-quarter 2016 adjusted earnings of 13 cents per share, which beat the Zacks Consensus Estimate by 6 cents.
CENT: 25.86 (-0.30), NTRI: 28.91 (+0.12), WMT: 71.40 (+0.26)

VistaGen Therapeutics Appoints Jerry Gin, Ph.D., MBA to its Board of Directors
PR Newswire - Wed Mar 30, 7:05AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA) (VistaGen or the Company), a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system (CNS), today announced that it has appointed Jerry Gin, Ph.D., MBA to its Board of Directors. Dr. Gin has also been appointed as a member of the Company's Audit Committee.

VistaGen Therapeutics Bolsters Clinical and Regulatory Advisory Board with Appointments of Distinguished Key Opinion Leaders in Depression
PR Newswire - Tue Mar 22, 7:05AM CDT
VistaGen Therapeutics Inc. (OTCQB: VSTA) (VistaGen or the Company), a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system (CNS), today announced that it has appointed Sanjay Mathew, M.D. and Thomas Laughren M.D. to the Company's Clinical and Regulatory Advisory Board to join its existing members, Gerard Sanacora, M.D., Ph.D. and Maurizio Fava, M.D. The Company also announced today the appointment of Dr. Fava as Chairman of this Board.

VistaGen Secures Exclusive Worldwide Commercial Rights to Three Proprietary Stem Cell Technologies from University Health Network
PR Newswire - Wed Dec 23, 6:53AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat depression, cancer and diseases and disorders involving the central nervous system, today announced that it has secured exclusive worldwide commercial rights to three patent-pending stem cell technologies from University Health Network (UHN), Canada's largest research hospital. The newly licensed technologies were discovered and developed by distinguished UHN researcher, Dr. Gordon Keller, Director of UHN's McEwen Centre for Regenerative Medicine (McEwen Centre), one of the world's leading centers for stem cell and regenerative medicine research, and relate to the development of stem cells into heart, liver and cartilage cells for multiple potential commercial applications, including drug rescue and regenerative therapies for heart disease, liver disease and osteoarthritis. VistaGen now holds a total of five licenses to stem cell technologies developed in collaboration with UHN, the McEwen Centre and Dr. Keller.

VistaGen Announces First Patient Dosed in NIH-Sponsored Phase 2A Study of Orally Available AV-101 in Major Depressive Disorder
PR Newswire - Tue Nov 03, 6:53AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat depression, cancer and diseases and disorders involving the central nervous system (CNS), today announced that the first patient has been dosed in a Phase 2A study of its orally available AV-101 in adult patients with treatment-resistant Major Depressive Disorder (MDD). The study is being fully funded by the U.S. National Institutes of Health (NIH), and is being conducted at the U.S. National Institutes of Mental Health (NIMH), under the direction of Principal Investigator, Carlos Zarate, Jr., M.D. Dr. Zarate is Chief, Section on the Neurobiology and Treatment of Mood Disorders and Chief of Experimental Therapeutics and Pathophysiology Branch (ETPB) at the NIMH, and Clinical Professor of Psychiatry and Behavioral Sciences at The George Washington University. VistaGen received clearance from the U.S. Food and Drug Administration (FDA) and the NIH to initiate the study in July 2015, after entering into a Cooperative Research and Development Agreement (CRADA) with the NIMH in February 2015.

Dr. Maurizio Fava, Internationally Renowned Expert in the Field of Depression, Joins VistaGen's Clinical and Scientific Advisory Board
PR Newswire - Wed Oct 07, 6:53AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat depression, cancer and diseases and disorders involving the central nervous system (CNS), today announced that Maurizio Fava, MD, a world renowned expert in depressive disorders and psychopharmacology, has joined the Company's Clinical and Scientific Advisory Board, effective immediately. Dr. Fava is Director of the Division of Clinical Research of the Massachusetts General Hospital (MGH) Research Institute, Executive Vice Chair, Department of Psychiatry at MGH, and Executive Director of the MGH Clinical Trials Network and Institute (CTNI), as well as Slater Family Professor of Psychiatry at Harvard Medical School. He co-developed, with Dr. David Schoenfeld, Professor of Biostatistics at the Harvard School of Public Health, a novel, patented clinical trial design which increases the probability of detecting a positive drug response, while markedly reducing sample size requirements for the trial, by reducing the potentially high placebo response sometimes found in depression, and other, clinical trials.

Vista Receives coverage and issued significant U-P-G-R-A-D-D-E
M2 - Fri Jun 19, 10:19AM CDT
Companies mentioned in this article: Vistagen Therapeutics Inc (OTC: VSTA), Digital Ally (NASDAQ: DGLY), athenaHealth (NASDAQ: ATHN), Juno (NASDAQ: JUNO), Kite Pharma (NASDAQ: KITE) and Virgin America (NASDAQ: VA)
SIGM: 7.50 (-0.05), RAVE: 3.99 (unch), CHFN: 13.09 (-0.11), ABCO: 42.18 (+0.12), TI: 9.01 (-0.01), XXIA: 11.71 (-0.03), H: 54.05 (-0.03), ATHN: 122.89 (+0.80), VCRA: 16.48 (-0.23), IMPR: 19.18 (unch), VA: 55.86 (-0.11), VAR: 96.31 (+0.94), KITE: 58.04 (-0.60), CVS: 93.08 (-0.18), JUNO: 31.81 (-0.45), HMSY: 21.93 (+0.19), OMCL: 38.03 (+0.57), DGLY: 6.16 (+0.07), CERN: 65.00 (+0.36), PINC: 31.50 (+0.65), SHOR: 8.00 (+0.02)

Biotech ETFs open higher a day after hitting record highs
M2 - Fri Jun 19, 10:12AM CDT
Companies and ETFs mentioned in this article: Nasdaq Biotechnology ETF (NYSE: IBB), SPDR S&P Biotech ETF (NYSE: XBI), Gilead Sciences (NASDAQ: GILD), Vistagen Therapeutics Inc (OTC: VSTA), and Axovant Sciences (NYSE: AXON).
AXON: 16.61 (-0.08), GILD: 78.17 (-1.60), XBI: 61.04 (-0.06), IBB: 283.87 (-1.27)

Shopify's off and running
M2 - Thu May 21, 10:19AM CDT
Companies mentioned in this article: Shopify Inc. (SHOP), Banjo and Matilda (BANJ), Source Financial (SRCF), and VistaGen (VSTA)
SHOP: 41.39 (-0.13)

Follow the Gileader
M2 - Thu May 07, 8:26AM CDT
Companies mentioned in this article: Gilead Sciences (NASDAQ: GILD), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Synageva BioPharma Corp. (NASDAQ: GEVA), VistaGen (OTCQB: VSTA), Juno Therapeutics, Inc. (JUNO) and Fate Therapeutics, Inc. (FATE)
GEVA: 238.60 (+2.80), GILD: 78.17 (-1.60), ALXN: 127.99 (-1.64), JUNO: 31.81 (-0.45)

Gilead Sciences Knocks it out of the Park, but does that mean that Biopharma is Undervalued?
M2 - Mon May 04, 7:40AM CDT
After taking a beating to close out April, with iShares Nasdaq Biotechnology (NASDAQ: IBB) losing nearly 10% off the mid-month highs, the biotech sector may have gotten the shot in the arm it need for the next leg up. By generating $2.94 a share profits, more than doubling the previous year's quarterly profits, on $7.6 billion revenues, a better than 50% improvement in year-over-year revenues, Gilead Sciences (NASDAQ: GILD) destroyed its earnings and 2015 sales guidance to the $28-29 billion range. By doing so, Gilead may have just kick started the next biopharma bull run.
GILD: 78.17 (-1.60), PFE: 35.11 (+0.29), IBB: 283.87 (-1.27), GSK: 43.61 (+0.06), CAPN: 1.02 (-0.03)

BioPharmas are running the FDA Fast Track to Success
M2 - Wed Apr 22, 4:06AM CDT
Biopharma listings tend to reward investors early and often. One of my favorite plays in this sector is the 505(b)(2), an FDA provision that's best known as the fast track announcement. Since these announcements are often made before the street is familiar with the company, or the developmental treatment, the biopharma premium is not priced into the listings. Fast Track designation may be awarded to medicines that are intended to treat a serious or life-threatening disease, or condition, and demonstrate the potential to address unmet medical needs. In addition to reducing the development and approval timeline, the provision can also reduce the financial outlay needed to commercialize the respective products.
HZNP: 18.84 (-0.59), ABIO: 2.98 (+0.13), ORPN: 1.66 (-0.05), DYAX: 38.04 (-0.37)

VistaGen and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder
Marketwired - Tue Feb 17, 8:04AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company developing innovative medicine for depression and conditions involving the central nervous system (CNS), has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Institute of Mental Health (NIMH), part of the U.S. National Institutes of Health (NIH). Under the CRADA, VistaGen and the NIMH will collaborate on an NIH-sponsored Phase 2 clinical study of AV-101, VistaGen's orally-active NMDA receptor modulator, in subjects with Major Depressive Disorder (MDD). MDD is a widespread and debilitating mental disorder affecting millions worldwide, including nearly 7% of U.S. adults.

Dr. Gerard Sanacora Joins VistaGen's Clinical and Scientific Advisory Board
Marketwired - Thu Feb 05, 9:53AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company developing innovative medicine for depression and conditions involving the central nervous system, has added Gerard Sanacora PhD, MD, Professor of Psychiatry at the Yale School of Medicine and Director of the Yale Depression Research Program, to its Clinical and Scientific Advisory Board. Dr. Sanacora will focus on Phase 2 and Phase 3 clinical development of AV-101, VistaGen's orally-active NMDA receptor modulator for treating Major Depressive Disorder (MDD). AV-101 is a unique prodrug candidate that produces, in the brain, 7-chlorokynurenic acid (7-Cl-KYNA), one of the most potent and selective antagonists of the required glycine-binding site of the NMDA receptor, which results in down-regulation of NMDA signaling.

VistaGen Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder
Marketwired - Wed Nov 19, 2:42PM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company focused on innovative medicine for depression, cancer and diseases and disorders involving the central nervous system (CNS), has signed a Letter of Intent to enter into a Cooperative Research and Development Agreement (CRADA) with the National Institute of Mental Health (NIMH), part of the National Institutes of Health (NIH), to collaborate on a NIMH-sponsored Phase 2 clinical study of VistaGen's lead drug candidate, AV-101, in Major Depressive Disorder, one of the most common mental disorders in the U.S.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 379

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 382

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 344

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 15

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 160

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 59

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 58

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 370

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 88

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 358

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading

Top 5 Most Recently Viewed Articles

The GEO Group Expands Services with $70 Million Investment

Updated Category News Views 182

The GEO Group's Major Investment in Service Expansion The GEO Group, Inc. (NYSE: GEO) has made headlines with its recent announcement of a substantial $70 million investment aimed at enhancing its capabilities in providing services to U.S. Immigration and Customs Enforcement (ICE). As the leading service provider for ICE, GEO currently manages approximately 21,000...

Continue Reading
NJ's $21.3M Water Fix Fights PFAS, Boosts AWK

Updated Category News Views 216

Water Woes Culminate in Triumph Alright, folks, you don't often see New Jersey in the headlines for anything groundbreaking in the right way, but here we are. The big news is a hefty $21.3 million project completion that finally puts some ammo against the notorious PFAS chemicals. If you've got any skin in the utility game or just a stake in clean water, this one's been...

Continue Reading
Volkswagen's CEO Calls for Major Union Concessions Amid Challenges

Updated Category News Views 69

Volkswagen Prepares for Union Negotiations Amid Growing Tensions Volkswagen, a major player in the automotive industry, is gearing up for important negotiations with labor unions. These talks are taking place as the company faces rising tensions and significant challenges within the industry. The CEO, Oliver Blume, anticipates that unions will propose measures focused on...

Continue Reading
Exploring the Growth of CAE Market and Key Players in 2025

Updated Category News Views 248

Overview of the Computer-Aided Engineering (CAE) Market The Computer-aided Engineering (CAE) market is experiencing significant growth, projected to reach approximately USD 19.96 billion by 2030. This remarkable rise is spurred on by a compound annual growth rate (CAGR) of 10.2% from its previous valuation of USD 12.28 billion. Driving Forces Behind Market Growth A major...

Continue Reading
Investors of RCI Hospitality Holdings Urged to Act Now

Updated Category News Views 201

Investors Alert for RCI Hospitality Holdings, Inc. Attention all investors in RCI Hospitality Holdings, Inc. (NASDAQ: RICK)! Recent developments concerning the company have raised significant concerns, particularly for shareholders who may have suffered financial losses. A class action lawsuit has been initiated and it’s essential for affected investors to be aware of...

Continue Reading